Vicapsys Life Sciences, Inc. (VICP)
1.45
0.00 (0.00%)
USD |
OTCM |
Aug 21, 16:00
Vicapsys Life Sciences Debt to Equity Ratio : -0.1759 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | -0.1759 |
| March 31, 2025 | -0.189 |
| December 31, 2024 | -0.2008 |
| September 30, 2024 | -0.2188 |
| June 30, 2024 | -0.1889 |
| March 31, 2024 | -0.2049 |
| December 31, 2023 | -0.1835 |
| September 30, 2023 | -0.2304 |
| June 30, 2023 | -0.2406 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| June 30, 2019 | |
| December 31, 2018 | 0.00 |
| March 31, 2010 | -0.737 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 0.1325M |
| Total Liabilities (Quarterly) | 3.682M |
| Shareholders Equity (Quarterly) | -3.549M |
| Current Ratio | 0.036 |
| Net Debt Paydown Yield | -0.07% |